Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
1. Claims 1-37 are currently pending and under examination.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
2. Claim 1, 27-28 and 31 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 28 and 31 are rendered vague and indefinite by the use of the phrase “….having all of the identifying characteristics of the strain deposited”. It is unclear what is meant by said phrase, as it is not explicitly defined in the specification. What constitutes “identifying characteristics” as they are not defined in the claim or within the specification? What core features/structures must be maintained? As written, it is impossible to determine the metes and bounds of the claimed invention.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
3. Claims 1-37 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-16, 18-28, 35, 39-49, 52 and 54-57 of U.S. Patent No. 11,779,612 B2. Although the claims at issue are not identical, they are not patentably distinct from each other because the pending claims are drawn to a method of treatment of cancer, comprising administering an immunostimulatory bacterium and a second anti-cancer agent, wherein the immunostimulatory bacterium comprises a plasmid that encodes an anti-cancer therapeutic product; the genome of the immunostimulatory bacterium is modified so that the bacterium does not produce flagellin, whereby the bacterium is taken up by phagocytic cells and does not actively infect cells; and the second anti-cancer agent is administered before, concomitantly with, after, or intermittently with, the immunostimulatory bacterium.
The combination of the following patented claims anticipates and/or makes obvious the co-pending claims.
1. A method of treatment of cancer that comprises a solid tumor or a hematological malignancy in a subject, comprising administering an immunostimulatory bacterium, wherein: the immunostimulatory bacterium comprises a plasmid that encodes an anti-cancer therapeutic product; the genome of the immunostimulatory bacterium is modified so that, compared to the bacterium without the genome modifications, the bacterium has increased ability to infect tumor-resident immune cells, and has reduced ability to infect or does not infect epithelial cells; and the anti-cancer therapeutic product is expressed under the control of one or more eukaryotic regulatory sequences, whereby the product is expressed in the tumor-resident immune cells in the subject.
6. The method of claim 1, wherein the treatment comprises combination therapy in which a second anti-cancer agent or treatment is administered.
12. The method of claim 11, wherein the immunostimulatory bacterium is a Salmonella typhimurium strain.
13. The method of claim 12, wherein the Salmonella typhimurium strain is derived from a wild-type Salmonella typhimurium strain having all of the identifying characteristics of the strain deposited under ATCC accession no. 14028, or is the strain deposited under ATCC accession no. 14028.
14. The method of claim 1, wherein: the eukaryotic regulatory sequences comprise a eukaryotic promoter; the genome of the immunostimulatory bacterium is modified, whereby the bacterium lacks flagella to thereby reduce infection of epithelial cells and increase infection of tumor-resident immune cells relative to the wild-type bacterium; and the wild-type bacterium has flagella.
15. The method of claim 1, wherein the genome of the immunostimulatory bacterium is modified, whereby the bacterium is msbB−/pagP−.
16. The method of claim 14, wherein the genome of the immunostimulatory bacterium is modified, whereby the bacterium is msbB−/pagP−.
47. A method of treatment of cancer, comprising administering an immunostimulatory bacterium to a subject with cancer, wherein:
the immunostimulatory bacterium comprises a plasmid that encodes a therapeutic product under the control of a eukaryotic promoter;
the immunostimulatory bacterium comprises one or more genome modification(s), whereby the bacterium has penta-acylated lipopolysaccharide (LPS); and
the immunostimulatory bacterium lacks flagella, wherein the wild-type bacterium comprises flagella.
4. Claims 1-37 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-41 of U.S. Patent No. 12,226,439 B2. Although the claims at issue are not identical, they are not patentably distinct from each other because the pending claims are drawn to a method of treatment of cancer, comprising administering an immunostimulatory bacterium and a second anti-cancer agent, wherein the immunostimulatory bacterium comprises a plasmid that encodes an anti-cancer therapeutic product; the genome of the immunostimulatory bacterium is modified so that the bacterium does not produce flagellin, whereby the bacterium is taken up by phagocytic cells and does not actively infect cells; and the second anti-cancer agent is administered before, concomitantly with, after, or intermittently with, the immunostimulatory bacterium.
The patented claims are drawn to a method of treatment of cancer, comprising administering an immunostimulatory bacterium, wherein: the immunostimulatory bacterium comprises a plasmid that encodes an anti-cancer therapeutic product; the genome of the immunostimulatory bacterium is modified so that the bacterium is taken up by phagocytic cells and does not infect epithelial cells; and the bacterium without the modifications does infect epithelial cells.
The patented claims are further drawn to a method of treatment of cancer in a subject, comprising administering an immunostimulatory bacterium, wherein: the immunostimulatory bacterium comprises a plasmid that encodes a therapeutic product; nucleic acid encoding the therapeutic product is under control of a eukaryotic promoter; and the immunostimulatory bacterium comprises genome modifications, whereby the bacterium is pagP-/msbB-.
The combination of the patented claims make obvious and/or anticipates co-pending claims.
Conclusion
5. No claim is allowed.
6. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.
WO 2010/010983 A1- recombinant bacteria with gene mutations in the MsbB genes.
WO 01/14579 A2- attenuated salmonella modified to encode anti-tumor proteins.
7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAKIA J JACKSON-TONGUE whose telephone number is (571)272-2921. The examiner can normally be reached Monday-Friday 930AM-530PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anne Gussow can be reached at (571) 272-6047. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/LAKIA J JACKSON-TONGUE/Examiner, Art Unit 1645 September 29, 2026
/BRIAN GANGLE/Primary Examiner, Art Unit 1645